Low-dose aspirin significantly reduced colorectal cancer recurrence in patients with PI3K pathway gene alterations, nearly halving recurrence rates over three years compared to placebo. The study ...

Second clinical candidate from HUTCHMED’s next-generation ATTC platform —— Leveraging synergy through simultaneous inhibition of PAM pathway ...

Antioxidant-1 may promote HCC carcinogenesis through the activation of the c-Myb/PI3K/AKT pathway and the inhibition of copper accumulation and oxidative stress. Despite advancements in diagnostic and ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations in ...

– Entered collaboration with Pfizer to evaluate triplet combination of STX-478 + atirmociclib + fulvestrant in frontline patients with PI3Kα-mutated HR+/HER2- metastatic breast cancer; trial ...

Zovegalisib (RLY-2608) is the first pan-mutant-selective PI3Kα inhibitor, binding a novel allosteric site distinct from ...

Hong Kong, Shanghai Friday, March 6, 2026, 10:00 Hrs [IST] ...

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target ...